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Abstract
The b site APP cleaving enzyme 1 (BACE1) is the rate-limiting b-secretase enzyme in the amyloidogenic processing of APP
and Ab formation, and therefore it has a prominent role in Alzheimer’s disease (AD) pathology. Recent evidence suggests
that the prion protein (PrP) interacts directly with BACE1 regulating its b-secretase activity. Moreover, PrP has been
proposed as the cellular receptor involved in the impairment of synaptic plasticity and toxicity caused by Ab oligomers.
Provided that common pathophysiologic mechanisms are shared by Alzheimer’s and Creutzfeldt-Jakob (CJD) diseases, we
investigated for the first time to the best of our knowledge a possible association of a common synonymous BACE1
polymorphism (rs638405) with sporadic CJD (sCJD). Our results indicate that BACE1 C-allele is associated with an increased
risk for developing sCJD, mainly in PRNP M129M homozygous subjects with early onset. These results extend the very short
list of genes (other than PRNP) involved in the development of human prion diseases; and support the notion that similar to
AD, in sCJD several loci may contribute with modest overall effects to disease risk. These findings underscore the interplay in
both pathologies of APP, Ab oligomers, ApoE, PrP and BACE1, and suggest that aging and perhaps vascular risk factors may
modulate disease pathologies in part through these key players.
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Introduction
Alzheimer’s (AD) and Creutzfeldt-Jakob (CJD) diseases are
distinct fatal neurodegenerative pathologies sharing common
epidemiologic and pathophysiologic mechanisms [1], including
the deposition of disease specific pathognomonic amyloidogenic
proteins [1–5], pathways involved in amyloid generation and
clearance [1,5,6], and genetic and vascular risk factors [3,7,8].
Recently, we have shown a genetic cross-interaction between
APOE and PRNP, the major genetic risk factors [9–11] in the
sporadic forms of AD and CJD [12].
In AD, the amyloid deposits consist predominantly of a peptide
of 39–43 amino acids called amyloid-b peptide (Ab) [13,14],
resulting from the pathogenic processing of the amyloid b
precursor protein (APP) by sequential cleavage by b-secretase
and c-secretase [15,16]. In CJD, when the deposition occurs, the
amyloid consists of a protease-resistant and aggregated fragment
derived from the cellular prion protein (PrP) isoform [17–21].
b-secretase, also called b site APP cleaving enzyme 1 (BACE1),
is a membrane-bound aspartyl protease involved as the rate-
limiting enzyme in the amyloidogenic processing of APP and Ab
formation [22]. An increased BACE1 activity that correlates with
Ab peptides load has been observed in the brain of sporadic AD
patients [23–25]. Recent evidence suggests that PrP protein
interacts directly with BACE1 regulating its b-secretase activity
[25–27]. Griffiths et al suggested [25] that the interaction of PrP
with the N-terminal prodomain (residues 22–45) of the immature,
Golgi-localized form of BACE1 results in a retention of BACE1 in
the secretory pathway and a reduced presence at the cell surface
and endosomes where it should exert its secretase function on
APP.
Some authors have reported the association between BACE1
polymorphisms and the risk of developing AD, although this link is
still matter of discussion. However, at present there are no
association studies of BACE1 polymorphisms with prion diseases.
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In this paper, we investigated for the first time a possible
association of a common synonymous BACE1 polymorphism at
codon 262 (NM_012104.3:c.786G.C, rs638405) with sporadic
CJD (sCJD).
Results
We have analyzed the risk of sCJD associated with a BACE1
polymorphism (rs638405) and their potential interaction with
PRNP. For this purpose, the study population included 237 sCJD
patients and 329 healthy controls. The demographic description of
these populations is shown in Figure 1.
Age distributions for the populations analyzed followed non-
normal distributions. We found statistically significant age
differences between sCJD and control populations (p,0.001).
However, no statistically significant differences were observed in
gender distribution (p = 0.14). No statistically significant differenc-
es were found between definitive and probable sCJD cases for any
of the parameters studied.
The allelic and genotypic distributions of BACE1 and PRNP
genes were in Hardy-Weinberg equilibrium in the populations
studied, with the exception of PRNP in sCJD. We observed an
increased risk of sCJD for individuals homozygous at codon 129 in
the PRNP gene (OR = 5.01, CI 95% = 3.29–7.62, p = 5.5610214)
as previously reported for a similar population [12] and in
agreement with previous reports worldwide. The distributions of
BACE1 genotypes stratified by age and the polymorphic codon
129 of PRNP are shown in Table 1.
The analysis of BACE1 polymorphism effect on sCJD (Table 2)
showed a non-significant association trend for BACE1 C-allele
carriers (OR = 1.56, p = 0.052) for the whole population. Post-hoc
power analysis of this result, assuming that the probability of
exposure (C+ carriers) is 0,769 for controls, and 0.835 for cases,
indicated that we are able to reject the null hypothesis that the
odds ratio equals 1 with probability (power) of 0.629 for an alpha
error (type I) equal to 0.05, in a model of inequality of proportions
for two independent groups by Fisher9s exact test. Analogous
power analysis by using a logistic regression model and assuming a
binomial distribution for the independent variable (BACE1
polymorphism) yielded a slightly lower power value of 0.536.
However, after stratification by PRNP genotypes, a clear
association was found within the PRNP M129M homozygous
stratum (OR = 2.46, CI 95% = 1.29–4.69, p = 0.006). Interesting-
ly, the BACE1 C-allele risk appears to increase with increasing
numbers of PRNP-M129 alleles (Table 2).
As described in the methods section, this study is composed of
two distinct sCJD populations coming from the Carlos III Institute
of Health, Madrid, Spain (ISCIII, n = 166) or the Institute of
Neuropathology (INP), IDIBELL-Hospital Universitari de Bell-
vitge, Barcelona, Spain (INP-IDIBELL, n = 71). In order to check
for results consistency, we analysed the ISCIII sCJD cases and
used the INP-IDIBELL cases as internal replication population.
For both populations, we found a consistent association of BACE1
C-allele with sCJD exclusively in the PRNP M129M homozygous
stratum: OR = 2.16, CI 95% = 1.10–4.25, p = 0.026 for ISCIII
population; OR = 4.82, CI 95% = 1.33–17.45, p = 0.016 for INP-
IDIBELL population.
In order to explore the influence of age on this risk factor, cases
and controls were divided into two groups according to the
median age for these populations pooled together (onset before
and onset at or after 71 years old). Analysis of BACE1
polymorphism risk on different age strata indicated that the
association of BACE1 C-allele found in the M129M homozygous
stratum was mainly driven by individuals with early onset
(OR = 3.99, 95% CI = 1.51–10.49, p = 0.005) (see Table 2).
These results suggested a potential interaction between BACE1
and PRNP genes. In order to measure the size and significance of
the possible interaction, we performed a synergy factor (SF)
analysis. Taking as reference those individuals without these traits
Figure 1. Demographic description and histogram of age distribution at clinical onset for sCJD (left) and sample procurement for
controls (right) adjusted to normal distribution curves. Statistically significant differences between sCJD and control populations were
observed for age (p,0.001) but not for gender distribution (p = 0.14).
doi:10.1371/journal.pone.0043926.g001
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(PRNP M129V heterozygous and BACE1 GG), we observed that
PRNP M129M homozygous subjects had a 2.46-fold increased risk
of developing sCJD, while the risk associated with BACE1 C-allele
carriers was 0.94. When these genotypes were analyzed jointly,
subjects carrying both traits (PRNP M129M homozygous and
BACE1 C-allele carriers) had a 6.09-fold increased risk of
developing sCJD than subjects without these traits. Synergy
analysis yielded a SF of 2.63, which was not statistically significant
(p = 0.059). However, after stratification by age (cut-off at 71 years
old), a SF of 4.21 (p = 0.037) was obtained for subjects with onset
before 71 years old, indicating that interaction between these two
genes was age dependent. Similar analysis taking as reference
PRNP V129 carriers (M129V+V129V) and BACE1 GG yielded a
significant SF of 2.82 (p = 0.020). For individuals with early onset
(,71 years old) we also observed a significant interaction with a
SF of 4.29 (p = 0.022). Further analysis by a logistic regression
model controlled by age, sex and PRNP homozygosis and using the
number of PRNP-M129 alleles and the BACE1-C allele status as
covariables indicated that the interaction factor ‘‘PRNP-M129
alleles’’6‘‘BACE1-C allele status’’ was statistically significant
(p = 0.016).
Additionally, we explored the influence of BACE1 polymor-
phism on disease duration and age at onset in sCJD population,
but we did not observe any significant association between these
factors in BACE1 C-allele carriers compared to BACE1 GG
individuals (data not shown).
Discussion
Here, we have analyzed for the first time the distribution of
BACE1 rs638405 polymorphism on a sCJD population. Our
results indicate that BACE1 polymorphism is associated with risk
for developing sCJD, which is mainly driven by PRNP M129M
homozygous subjects. The effect of BACE1 polymorphism appears
to be age-dependent, being more relevant in earlier onset sCJD
patients, where a genetic interaction is observed between BACE1
and the major susceptibility marker for human prion diseases
(PRNP).
BACE1 is a type 1 transmembrane aspartic protease with a key
role on Ab formation [28,29], and in the production of the
amyloid precursor protein intracellular domain (AICD) that plays
a role in transcriptional transactivation [30]. Recently, it has been
Table 1. BACE1 (rs638405) and PRNP codon 129 genotypic frequencies in control subjects and sCJD patients.
BACE1 n (%)
Age at onset
(years) 129 PRNP genotypic frequency, n (%)
Genotypes ,71 $ 71 M129M M129V V129V
Control subjects CC 108 41 67 38 52 18
(32.8) (28.7) (36.0) (29.9) (32.1) (45.0)
CG 145 68 77 57 73 15
(44.1) (47.5) (41.4) (44.9) (45.1) (37.5)
GG 76 34 42 32 37 7
(23.1) (23.8) (22.6) (25.2) (22.8) (17.5)
Total 329 143 186 127 162 40
(100.0) (100) (100) (100.0) (100.0) (100.0)
sCJD cases CC 89 54 35 55 19 15
(37.6) (40.9) (33.3) (35.3) (43.2) (40.5)
CG 109 58 51 80 15 14
(46.0) (43.9) (48.6) (51.3) (34.1) (37.8)
GG 39 20 19 21 10 8
(16.5) (15.2) (18.1) (13.5) (22.7) (21.6)
Total 237 132 105 156 44 37
(100.0) (100) (100) (100.0) (100.0) (100.0)
doi:10.1371/journal.pone.0043926.t001
Table 2. Odds ratios for the association between sCJD and BACE1 C-allele carriers at rs638405 among different strata defined by
PRNP codon 129 genotypes.
All subjects Onset before 71 y Onset at or after 71 y
129 PRNP genotypes OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
All subjects 1.56 (1.00–2.43) 0.052 1.97 (1.03–3.77) 0.039 0.94 (0.57–1.56) 0.82
M129M 2.46 (1.29–4.69) 0.006 3.99 (1.51–10.5) 0.005 1.79 (0.74–4.34) 0.20
M129V 0.95 (0.41–2.20) 0.91 0.93 (0.33–2.68) 0.89 1.09 (0.27–4.50) 0.90
V129V 0.55 (0.16–1.89) 0.34 0.23 (0.10–5.06) 0.35 1.03 (0.21–5.11) 0.97
doi:10.1371/journal.pone.0043926.t002
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suggested that the cellular form of prion protein, PrPC, participates
in a feedback loop controlling Ab production [31,32]. Moreover,
PrPC has been proposed as the cellular receptor of toxic Ab
oligomers [33,34]. In AD, the feedback loop appears to be
disrupted by the binding of Ab oligomers to PrPC, preventing
BACE1 regulation [31,32]. According to this, higher levels of
BACE1 activity may modulate the production of key players of
AD and prion pathologies by increasing the production of both Ab
and PrP via AICD signalling [27]; although this model has been
recently questioned [35].
Since BACE1 does not participate in PrP processing [31],
alterations of BACE1 activity could not directly explain the
abnormal metabolism of PrP in sCJD. However, as the processing
of APP by BACE1 is a key step for the production of Ab peptides,
and AICD in turn up-regulates PrP expression, increased levels of
BACE1 could be related to higher cellular levels of PrP that are
associated with increased susceptibility to prion diseases [36].
Moreover, other secretases, such as ADAM10, are involved both
in APP a-cleavage and PrP shedding [37,38]. In a cellular context,
BACE1 and ADAM10 are in competition for their substrates [39];
and changes in the levels of one of them perturb the levels of the
other [28]. Therefore, it is likely that an increase of BACE1
activity may modulate ADAM10 activity, leading to PrP
expression and shedding perturbations in vivo [37,40]. In this
sense, increased levels of BACE1 activity have been consistently
found in CSF of AD patients [41–48], as well as in sCJD [42].
However, opposite to AD, in sCJD increased levels of BACE1
activity in CSF did not correlate with higher levels of BACE1
protein in brain. Since amyloid plaques have been detected in
sCJD brain patients [49–51], these results suggest a disturbed Ab
metabolism in sCJD [42,52,53].
As BACE1 rs638405 is a silent polymorphism, a mechanism
independent of the primary sequence of BACE1 protein may be
involved in the potential functional expression of this SNP.
Interestingly, we found that BACE1 rs638405 may exert its effect
by altering the activity of exonic splicing enhancers (ESE). Specific
analysis of ESE regions predicted the presence of two ESE
sequences in the G-allele that are abolished in the C-allele within
the regions TGAT(G/C)A and ATGAT(G/C); therefore,
rs638405 potentially influences BACE1 gene expression or splicing.
Alternatively, it is possible that this polymorphism serves as a tag
SNP not directly involved in the pathogenic mechanism, but in
linkage disequilibrium with other regulatory SNP [54,55].
Besides PRNP, a small number of genes have been proposed to
be associated with human prion diseases, although with inconsis-
tent results [56–59]. We have recently reported that homozygosity
at codon 129 of PRNP act synergistically as risk factor for sCJD
with other genetic factors such as the APOE e4 allele [12] or
polymorphisms at the CALHM1 gene [60]. Very recently, a
relatively large genome-wide association study (GWAS) has
suggested additional genetic risk factors in human prion disorders
[61], although the necessarily small sample size and heterogeneity
of the disease have probably precluded the positive identification
of additional genes.
In summary, our results indicate that BACE1 rs638405 is
associated with an increased age-dependent risk for developing
sCJD. Unfortunately, this study is necessarily limited by the small
number of sCJD cases as it is a very rare disease. However, it must
be taken into account that the sCJD population studied represents
a big portion of cases diagnosed in Spain (a country with a
comparatively large 45-million population), many of them with a
post-mortem confirmed diagnosis. The inclusion of sCJD popu-
lations registered abroad – for instance from the EuroCJD
consortium-will surely provide more universal validity to the
results, but it would also carry an increased genetic variability to
the data of this already heterogeneous disease that may in turn
preclude the stratified analysis performed in this study.
In our view, the novelty and relevance of the present study lean
on the following facts: i) it represents the first association study of
BACE1 in sCJD, ii) these findings extend the very short list of genes
(other than PRNP) involved in the development of prion diseases in
humans; and support the notion that similar to AD, in sCJD
several loci may contribute with modest overall effects to disease
risk [12,62], iii) stratification and analysis of the interaction with
other risk genes have been revealed as a potent tool to unveil
hidden effects in general analyses, and it may in part explain the
lack of consensus in the analysis of BACE1 association studies in
AD [62–64], and iv) these results, together with our recently
published works [12,60], open up an interesting research line
regarding common genetics risk factors, and points to the interplay
in both pathologies of APP, Ab oligomers, ApoE, PrP and BACE1




The populations of analysis included 237 sCJD cases and 329
subjects with normal cognitive status. All subjects were Caucasians
of Spanish origin. Control samples were obtained from the
Neurology Departments of Hospital La Paz (Madrid) and the
Hospital Clı´nico San Carlos (Madrid) (n = 268), and National
Centre of Microbiology at the Carlos III Institute of Health,
Madrid, Spain (n = 61). All samples from sCJD cases analyzed in
this study were obtained from patients with suspected prion
diseases, submitted for diagnostic purposes under the guidelines of
the Spanish National Referral and Surveillance system analyzed at
the Institute of Neuropathology (INP), IDIBELL-Hospital Uni-
versitari de Bellvitge, Faculty of Medicine, University of
Barcelona, Hospitalet de LLobregat, Barcelona, Spain (n = 71)
or at the National Centre of Microbiology at the Carlos III
Institute of Health, Madrid, Spain (n = 166). For some sCJD cases,
clinical and neuropathological information was retrospectively
gathered from the Spanish National Registry of Human Trans-
missible Spongiform Encephalopathies. Among the 237 sCJD
cases, 187 (78.9%) were definitive, neuropathologically verified
patients, while 50 (21.1%) were probable sCJD cases. Genetic
cases of human prion diseases were excluded after complete DNA
sequencing of PRNP coding region.
Ethics Statement
The study was approved by the Bioethics and Animal Welfare
Committee from the Instituto de Salud Carlos III, Madrid, Spain;
and by the Ethical Research Committees from Universidad
Auto´noma de Madrid, Madrid, Spain. Control samples were
obtained with the adequate understanding and written consent of
subjects. All the data were analyzed anonymously, and clinical
investigations have been conducted according to the principles
expressed in the Declaration of Helsinki.
DNA Analysis
Total DNA was isolated from peripheral blood or cerebral tissue
following standard procedures. Genotyping of BACE1 polymor-
phism (rs638405) was determined by TaqManH probes (assay
code: C_3058171_1; _Applied Biosystems) as described by the
manufacturer. This polymorphism is located at position 28149 of
BACE1 RefSeqGene NG_029372 (version NG_029372.1,
GI:339409206) on human chromosome 11. The analysis of the
BACE1 rs638405 Risk in Sporadic CJD
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polymorphism at codon 129 of the PRNP gene (rs1799990) was
performed by DNA sequencing using specific primers [66]. No
new data on sequence variability of the genes analyzed was found.
Functional Prediction Analysis
Functional prediction analysis of BACE1 rs638405 was per-
formed by the use of FuncPred online software (http://snpinfo.
niehs.nih.gov/snpfunc.htm) [67]. Exonic splicing enhancers were
analyzed by RESCUE-ESE Web Server (http://genes.mit.edu/
burgelab/rescue-ese/) [68].
Statistical Methods
Statistical analyses of nominal or categorical variables were
performed by Fisher’s exact text or Pearson’s chi-square test.
Quantitative variables (age at onset, disease duration) did not
follow a normal distribution and were analyzed by non-parametric
statistical hypothesis contrast with Mann-Whitney U test. Uncon-
ditional logistic regression models controlled by age and gender
were used to compare genotypic and allelic frequencies and to
calculate association adjusted odds ratio (OR) and 95% confidence
intervals (CIs). The Hardy-Weinberg test for genotype frequency
distributions was performed on the observed genotype frequencies
for each population, with significance based on a standard
observed-expected chi-square distribution with one degree of
freedom. Deviation from normality of quantitative variables was
checked by the Kolmogorov-Smirnov statistic with Lilliefors’
significance. The synergy factor (SF), confidence intervals and
significance were calculated as described [69,70]. Most statistical
analyses were performed with PASW Statistics 19 software. Post-
host power analyses of association data were performed by either
Fisher9s exact test for a model of inequality of proportions for two
independent groups or z-test for a logistic regression model by
using the G*Power 3.1.3 software [71] based on the implemen-
tation of the procedure of Hsieh and collaborators [72].
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